December 16, 2020
Moderna’s COVID-19 vaccine is 94% effective at preventing symptomatic illness—and appears to prevent the spread of the virus, as well—according to an FDA briefing document released on Tuesday, December 15, NBC News reports. .
The findings set the Moderna vaccine up for emergency use authorization by the FDA—which would double the number of COVID-19 vaccines available, after the first shots of Pfizer-BioNTech’s vaccine were given to healthcare workers nationwide in the USA on Monday.
The high efficacy of the Moderna vaccine was achieved after two doses given 28 days apart. This is about the same level of effectiveness as the Pfizer-BioNTech vaccine.E
But there is also evidence that just one dose of Moderna’s may stop the virus’s spread. A second document published on the FDA website shows asymptomatic infection was reduced by 63% after the first shot.
Still, it is expected that regulators will require two doses of the vaccine for maximum protection, NBC News notes.
A committee independent of the FDA, the Vaccines and Related Biological Products Advisory Committee, will meet Thursday to decide whether to recommend that the agency greenlight the Moderna vaccine. The meeting will largely mirror the one from last Thursday, when the panel of experts ultimately recommended that the FDA authorize Pfizer’s vaccine.
The vaccines from both drugmakers use similar technology.
It is widely anticipated that the Moderna vaccine’s path to approval will be similar to Pfizer’s. Indeed, NBC reports, an authorization could come as soon as Friday. And officials with Operation Warp Speed are already planning for widespread distribution of the Moderna vaccine.
Research contact: @NBCNews